Celgene: targets FY 2019 sales of 17 bn to 17.2 bn dollars
(CercleFinance.com) - Celgene group, which is due to merge with Bristol-Myers (the deal is expected to be finalised in the third quarter of 2019), today announces that according to preliminary estimates, it has achieved its 2018 targets, with sales of around 15.
2 billion dollars.
For FY 2019, it expects revenues of between 17 billion and 17.2 billion dollars, for adjusted EPS of between 10.6 dollars and 10.8 dollars, respectively up 12% and 22% y-o-y.
Celgene will report its 2018 results in late January. Its merger with Bristol-Myers will result in a new "giant" in the pharmaceutical sector.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
2 billion dollars.
For FY 2019, it expects revenues of between 17 billion and 17.2 billion dollars, for adjusted EPS of between 10.6 dollars and 10.8 dollars, respectively up 12% and 22% y-o-y.
Celgene will report its 2018 results in late January. Its merger with Bristol-Myers will result in a new "giant" in the pharmaceutical sector.
Copyright (c) 2019 CercleFinance.com. All rights reserved.